164 related articles for article (PubMed ID: 38402373)
1. Improved Quality of Life in Patients with Psoriasis Receiving Apremilast: Real-World Data from the Netherlands.
van den Reek JMPA; van der Leest RJT; Thomas SE; Prevoo R; Plantenga ME; de Jong EMGJ
Adv Ther; 2024 Apr; 41(4):1594-1605. PubMed ID: 38402373
[TBL] [Abstract][Full Text] [Related]
2. The Needs of Patients with Psoriasis and Benefits of Apremilast in French Clinical Practice: Results from the Observational REALIZE Study.
Jullien D; Richard MA; Halioua B; Bessette C; Derancourt C; Bouloc A
Dermatol Ther (Heidelb); 2023 Jun; 13(6):1361-1376. PubMed ID: 37204608
[TBL] [Abstract][Full Text] [Related]
3. Real-World Apremilast Use for Treatment of Plaque Psoriasis in Italy: Patient Perspective, Characteristics, and Clinical Outcomes from the DARWIN Study.
Giofrè C; Fabbrocini G; Potenza C; Tiberio R; Gisondi P; Marasca C; Nuzzo CMA; Benincasa E; Bianchi L;
Adv Ther; 2023 Jul; 40(7):3021-3037. PubMed ID: 37171752
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trial.
Mrowietz U; Barker J; Conrad C; Jullien D; Gisondi P; Flower A; Reddy J; Paris M; Picard H; Jardon S; Augustin M
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):348-355. PubMed ID: 36300769
[TBL] [Abstract][Full Text] [Related]
5. Real-Life Effectiveness of Apremilast for the Treatment of Psoriasis in Belgium: Results From the Observational OTELO Study.
Ghislain PD; Lambert J; Lam Hoai XL; Hillary T; Roquet-Gravy PP; de la Brassinne M; Segaert S
Adv Ther; 2022 Feb; 39(2):1068-1080. PubMed ID: 34977985
[TBL] [Abstract][Full Text] [Related]
6. Apremilast Use in Severe Psoriasis: Real-World Data from Central and Eastern Europe.
Cetkovská P; Dediol I; Šola M; Kojanová M; Trčko K; Čarija A; Čeović R; Ledić-Drvar D; Kaštelan M; Hrabar A; Missoup MC; Mamun K
Adv Ther; 2023 Apr; 40(4):1787-1802. PubMed ID: 36862361
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of apremilast in biologic-naïve patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL study.
Ioannides D; Antonakopoulos N; Georgiou S; Chasapi V; Katsantonis I; Drosos A; Rigopoulos D; Antoniou C; Anastasiadis G; Bassukas I; Ioannidou D; Protopapa A; Neofotistou O; Krasagakis K; Aronis P; Papageorgiou M; Lazaridou E; Patsatsi A; Lefaki I; Roussaki-Schulze AV; Satra F; Anagnostopoulos Z; Papakonstantis M
J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1838-1848. PubMed ID: 34036627
[TBL] [Abstract][Full Text] [Related]
8. Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSO.
Reich K; Korge B; Magnolo N; Manasterski M; Schwichtenberg U; Staubach-Renz P; Kaiser S; Roemmler-Zehrer J; Gómez NN; Lorenz-Baath K
Dermatol Ther (Heidelb); 2022 Jan; 12(1):203-221. PubMed ID: 34913153
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study.
Augustin M; Kleyn CE; Conrad C; Sator PG; Ståhle M; Eyerich K; Radtke MA; Bundy C; Mellars L; Greggio C; Cordey M; Koscielny V; Griffiths CEM
J Eur Acad Dermatol Venereol; 2021 Jan; 35(1):123-134. PubMed ID: 32279378
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study.
Van Voorhees AS; Stein Gold L; Lebwohl M; Strober B; Lynde C; Tyring S; Cauthen A; Sofen H; Zhang Z; Paris M; Wang Y
J Am Acad Dermatol; 2020 Jul; 83(1):96-103. PubMed ID: 32032692
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
[TBL] [Abstract][Full Text] [Related]
12. Disease severity, treatment patterns, and quality of life in patients with moderate-to-severe psoriasis routinely managed with systemic treatment: results of the CRYSTAL observational study in Central and Eastern European countries.
Raam L; Hartmane I; Valiukevičienė S; Karamova AE; Telegdy E; Botev I; Marina D; Rubant S; Albuquerque T; Constantin MM
Front Immunol; 2024; 15():1410540. PubMed ID: 38846952
[TBL] [Abstract][Full Text] [Related]
13. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.
Thaçi D; Kimball A; Foley P; Poulin Y; Levi E; Chen R; Feldman SR
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):498-506. PubMed ID: 27538241
[TBL] [Abstract][Full Text] [Related]
14. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.
Papadavid E; Rompoti N; Theodoropoulos K; Kokkalis G; Rigopoulos D
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):1173-1179. PubMed ID: 29388335
[TBL] [Abstract][Full Text] [Related]
15. Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study.
Herranz P; Trasobares L; Mateu A; Martínez E; Ruiz-Villaverde R; Baniandrés O; Mataix Díaz J; Jiménez-Gómez N; Serra M; Ruiz Genao DP; Rivera N; Tercedor-Sánchez J; Garcia C; Cordey M; Herrera-Acosta E
Actas Dermosifiliogr (Engl Ed); 2021 May; ():. PubMed ID: 34052202
[TBL] [Abstract][Full Text] [Related]
16. A real-world, non-interventional, prospective study of the effectiveness and safety of apremilast in bio-naïve adults with moderate plaque psoriasis treated in the routine care in Greece - the 'APRAISAL' study.
Ioannides D; Antonakopoulos N; Chasapi V; Oikonomou C; Tampouratzi E; Lazaridou E; Rigopoulos D; Neofotistou O; Drosos A; Anastasiadis G; Rovithi E; Kalinou C; Papadavid E; Aronis P; Papageorgiou M; Protopapa A; Bassukas I; Lefaki I; Zafiriou E; Krasagakis K; Pokas E; Anagnostopoulos Z; Kekki A; Papakonstantis M
J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2055-2063. PubMed ID: 35451115
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial.
Fiorillo L; Becker E; de Lucas R; Belloni-Fortina A; Armesto S; Elewski B; Maes P; Oberoi RK; Paris M; Zhang W; Zhang Z; Arkin L
J Am Acad Dermatol; 2024 Jun; 90(6):1232-1239. PubMed ID: 38266683
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry.
Callis Duffin K; Mason MA; Gordon K; Harrison RW; Crabtree MM; Guana A; Germino R; Lebwohl M
Dermatology; 2021; 237(1):46-55. PubMed ID: 31962340
[TBL] [Abstract][Full Text] [Related]
19. Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL).
Lacour JP; Bewley A; Hammond E; Hansen JB; Horne L; Paul C; Reich K; Seneschal J; De Simone C; Sohrt A; Augustin M; Pellacani G
Dermatol Ther (Heidelb); 2020 Oct; 10(5):1099-1109. PubMed ID: 32761560
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria - results the APPRECIATE study.
Jonak C; Göttfried I; Perl-Convalexius S; Gruber B; Schütz-Bergmayr M; Vujic I; Weger W; Schicher N; Semlin L; Hemetsberger M; Cordey M; Sator P
Ther Adv Chronic Dis; 2023; 14():20406223231152785. PubMed ID: 36777399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
